异柠檬酸脱氢酶1（IDH1）抑制剂与化疗联合治疗IDH1突变型急性髓系白血病 - Suppr

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

作者信息

Gupta Charu, Kaulfuss Stefan, Görlich Kerstin, Othman Basem, Chaturvedi Anuhar, Heuser Michael

机构信息

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Bayer AG, Berlin, Germany.

出版信息

Ann Hematol. 2020 Jun;99(6):1415-1417. doi: 10.1007/s00277-020-04001-w. Epub 2020 Apr 15.

DOI:10.1007/s00277-020-04001-w

PMID:32296913

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7237524/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cc5/7237524/6f807c827404/277_2020_4001_Fig1_HTML.jpg

相似文献

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Ann Hematol. 2020 Jun;99(6):1415-1417. doi: 10.1007/s00277-020-04001-w. Epub 2020 Apr 15.

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.

Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. Epub 2016 May 5.

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Leuk Lymphoma. 2014 Jun;55(6):1431-4. doi: 10.3109/10428194.2013.840777. Epub 2013 Nov 1.

Inhibition of mutant IDH1 in acute myeloid leukaemia.

Lancet Oncol. 2015 Jan;16(1):e9. doi: 10.1016/S1470-2045(14)71140-4. Epub 2014 Nov 28.

IDH Inhibitors in AML-Promise and Pitfalls.

Curr Hematol Malig Rep. 2021 Apr;16(2):207-217. doi: 10.1007/s11899-021-00619-3. Epub 2021 Apr 30.

IDH1 inhibitor shows promising early results.

Cancer Discov. 2015 Jan;5(1):4. doi: 10.1158/2159-8290.CD-NB2014-178. Epub 2014 Dec 8.

mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.

Pediatr Hematol Oncol. 2020 Aug;37(5):431-437. doi: 10.1080/08880018.2020.1737284. Epub 2020 Mar 13.

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):769-772. doi: 10.1016/j.clml.2018.10.007. Epub 2018 Oct 21.

In brief: Two new drugs for AML.

Med Lett Drugs Ther. 2018 Mar 26;60(1543):e56.

引用本文的文献

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer.

Acta Pharm Sin B. 2023 Apr;13(4):1438-1466. doi: 10.1016/j.apsb.2022.12.019. Epub 2023 Feb 2.

本文引用的文献

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

Leukemia. 2020 Feb;34(2):416-426. doi: 10.1038/s41375-019-0582-x. Epub 2019 Oct 4.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.

Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780. doi: 10.1080/14656566.2017.1391216. Epub 2017 Oct 20.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

作者信息

Gupta Charu, Kaulfuss Stefan, Görlich Kerstin, Othman Basem, Chaturvedi Anuhar, Heuser Michael

机构信息

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Bayer AG, Berlin, Germany.

出版信息

Ann Hematol. 2020 Jun;99(6):1415-1417. doi: 10.1007/s00277-020-04001-w. Epub 2020 Apr 15.

DOI:10.1007/s00277-020-04001-w

PMID:32296913

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7237524/

Abstract

摘要

相似文献

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Ann Hematol. 2020 Jun;99(6):1415-1417. doi: 10.1007/s00277-020-04001-w. Epub 2020 Apr 15.

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.

Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. Epub 2016 May 5.

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Leuk Lymphoma. 2014 Jun;55(6):1431-4. doi: 10.3109/10428194.2013.840777. Epub 2013 Nov 1.

Inhibition of mutant IDH1 in acute myeloid leukaemia.

Lancet Oncol. 2015 Jan;16(1):e9. doi: 10.1016/S1470-2045(14)71140-4. Epub 2014 Nov 28.

IDH Inhibitors in AML-Promise and Pitfalls.

Curr Hematol Malig Rep. 2021 Apr;16(2):207-217. doi: 10.1007/s11899-021-00619-3. Epub 2021 Apr 30.

IDH1 inhibitor shows promising early results.

Cancer Discov. 2015 Jan;5(1):4. doi: 10.1158/2159-8290.CD-NB2014-178. Epub 2014 Dec 8.

mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.

Pediatr Hematol Oncol. 2020 Aug;37(5):431-437. doi: 10.1080/08880018.2020.1737284. Epub 2020 Mar 13.

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):769-772. doi: 10.1016/j.clml.2018.10.007. Epub 2018 Oct 21.

In brief: Two new drugs for AML.

Med Lett Drugs Ther. 2018 Mar 26;60(1543):e56.

引用本文的文献

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer.

Acta Pharm Sin B. 2023 Apr;13(4):1438-1466. doi: 10.1016/j.apsb.2022.12.019. Epub 2023 Feb 2.

本文引用的文献

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

Leukemia. 2020 Feb;34(2):416-426. doi: 10.1038/s41375-019-0582-x. Epub 2019 Oct 4.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.

Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780. doi: 10.1080/14656566.2017.1391216. Epub 2017 Oct 20.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5.

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献